Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy

被引:7
|
作者
Alves, Christiano R. R. [1 ,2 ,3 ]
Ha, Leillani L. [1 ,4 ]
Yaworski, Rebecca [5 ,6 ,7 ]
Sutton, Emma R. [5 ,6 ,7 ]
Lazzarotto, Cicera R. [8 ]
Christie, Kathleen A. [1 ,4 ,9 ]
Reilly, Aoife [5 ,6 ,7 ]
Beauvais, Ariane [5 ,6 ,7 ]
Doll, Roman M. [1 ,4 ,10 ,11 ]
de la Cruz, Demitri [12 ,13 ]
Maguire, Casey A. [12 ,13 ]
Swoboda, Kathryn J. [1 ,2 ,3 ]
Tsai, Shengdar Q. [8 ]
Kothary, Rashmi [5 ,6 ,7 ,14 ]
Kleinstiver, Benjamin P. [1 ,4 ,9 ]
机构
[1] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[3] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[5] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[6] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada
[7] Univ Ottawa, Ctr Neuromuscular Dis, Ottawa, ON, Canada
[8] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN USA
[9] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA
[10] Heidelberg Univ, Mol Biosci Canc Biol Program, Heidelberg, Germany
[11] German Canc Res Ctr, Heidelberg, Germany
[12] Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Charlestown, MA USA
[13] Harvard Med Sch, Program Neurosci, Boston, MA USA
[14] Univ Ottawa, Dept Med, Ottawa, ON, Canada
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
SURVIVAL MOTOR-NEURON; CRISPR-CAS9; NUCLEASES; SPLICING MODIFIER; NATURAL-HISTORY; SHAM CONTROL; GENOMIC DNA; MOUSE MODEL; NUSINERSEN; RISDIPLAM; THERAPY;
D O I
10.1038/s41551-023-01132-z
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Spinal muscular atrophy (SMA) is caused by mutations in SMN1. SMN2 is a paralogous gene with a C center dot G-to-T center dot A transition in exon 7, which causes this exon to be skipped in most SMN2 transcripts, and results in low levels of the protein survival motor neuron (SMN). Here we show, in fibroblasts derived from patients with SMA and in a mouse model of SMA that, irrespective of the mutations in SMN1, adenosine base editors can be optimized to target the SMN2 exon-7 mutation or nearby regulatory elements to restore the normal expression of SMN. After optimizing and testing more than 100 guide RNAs and base editors, and leveraging Cas9 variants with high editing fidelity that are tolerant of different protospacer-adjacent motifs, we achieved the reversion of the exon-7 mutation via an A center dot T-to-G center dot C edit in up to 99% of fibroblasts, with concomitant increases in the levels of the SMN2 exon-7 transcript and of SMN. Targeting the SMN2 exon-7 mutation via base editing or other CRISPR-based methods may provide long-lasting outcomes to patients with SMA.
引用
收藏
页码:118 / +
页数:17
相关论文
共 50 条
  • [21] ZPRI prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy
    Kannan, Annapoorna
    Jiang, Xiaoting
    He, Lan
    Ahmad, Saif
    Gangwani, Laxman
    BRAIN, 2020, 143 : 69 - 93
  • [22] The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
    Hensel, Niko
    Kubinski, Sabrina
    Claus, Peter
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [23] SMN-inducing compounds for the treatment of spinal muscular atrophy
    Lorson, Monique A.
    Lorson, Christian L.
    FUTURE MEDICINAL CHEMISTRY, 2012, 4 (16) : 2067 - 2084
  • [24] Therapeutic strategies for spinal muscular atrophy: SMN and beyond
    Bowerman, Melissa
    Becker, Catherina G.
    Yanez-Munoz, Rafael J.
    Ning, Ke
    Wood, Matthew J. A.
    Gillingwater, Thomas H.
    Talbot, Kevin
    DISEASE MODELS & MECHANISMS, 2017, 10 (08) : 943 - 954
  • [25] The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review
    Dosi, Claudia
    Masson, Riccardo
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [26] Update on drug treatment of spinal muscular atrophy
    Koelbel, Heike
    Hagenacker, Tim
    NERVENARZT, 2023, 94 (06): : 488 - 493
  • [27] Advances and limitations for the treatment of spinal muscular atrophy
    Day, John W.
    Howell, Kelly
    Place, Amy
    Long, Kimberly
    Rossello, Jose
    Kertesz, Nathalie
    Nomikos, George
    BMC PEDIATRICS, 2022, 22 (01)
  • [28] Base editing rescue of spinal muscular atrophy in cells and in mice
    Arbab, Mandana
    Matuszek, Zaneta
    Kray, Kaitlyn M.
    Du, Ailing
    Newby, Gregory A.
    Blatnik, Anton J.
    Raguram, Aditya
    Richter, Michelle F.
    Zhao, Kevin T.
    Levy, Jonathan M.
    Shen, Max W.
    Arnold, W. David
    Wang, Dan
    Xie, Jun
    Gao, Guangping
    Burghes, Arthur H. M.
    Liu, David R.
    SCIENCE, 2023, 380 (6642)
  • [29] SMN in spinal muscular atrophy and snRNP biogenesis
    Coady, Tristan H.
    Lorson, Christian L.
    WILEY INTERDISCIPLINARY REVIEWS-RNA, 2011, 2 (04) : 546 - 564
  • [30] Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: Applicability to preclinical therapy development for spinal muscular atrophy
    Mattis, Virginia B.
    Butchbach, Matthew E. R.
    Lorson, Christian L.
    JOURNAL OF NEUROSCIENCE METHODS, 2008, 175 (01) : 36 - 43